Cervista HPV Clinical Trial results published
Cervista® HPV HR demonstrates equal sensitivity and increased specificity compared to Hybrid Capture 2
In a large and demographically diverse prospective clinical trial, Cervista® HPV demonstrated clear clinical utility. The study’s clinical findings are being published in the August issue of Gynecologic Oncology2 and are available online at doi:10.1016/j.ygyno.2010.04.013. In this study:
- Sensitivity of the Cervista HPV HR test for detection of ≥CIN2 among women with ASC-US cytology was 92.8% (84.1-96.9) and the NPV was 99.1% (98.1-99.6).
- Sensitivity for detection of ≥CIN3 among women with ASC-US cytology was 100% (85.1-100) and the NPV was 100% (99.4-100).
- 16/18 genotyping test sensitivity of ≥CIN2 was 68.8 (56.6-78.8) and NPV was 96.0% (93.9-97.4).
- 16/18 genotyping test sensitivity of ≥CIN3 was 77.3 (56.6-89.9) and NPV was 99.0% (97.7-99.6).
